Evidence
Clin Res Hepatol Gastroenterol. 2024 May 3:102366. doi: 10.1016/j.clinre.2024.102366. Online ahead of print.
NO ABSTRACT
PMID:38705235 | DOI:10.1016/j.clinre.2024.102366
Estimated reading time: 1 minute(s)
Latest: Psychiatryai.com #RAISR4D Evidence
Cool Evidence: Engaging Young People and Students in Real-World Evidence
Real-Time Evidence Search [Psychiatry]
AI Research
Abnormal liver steatosis and fibrosis serum biomarker levels among psychiatric inpatients
🌐 90 Days
AI Virtual Reality Related Evidence Matrix
- Abnormal liver steatosis and fibrosis serum biomarker levels among psychiatric inpatients
- Use of PNPLA3, TM6SF2, and HSD17B13 for detection of fibrosis in MASLD in the general population
- The Pan Immune Inflammatory Value in Relation to Non-Alcoholic Fatty Liver Disease and Hepatic Fibrosis
- Resmetirom's Approval: Highlighting the Need for Comprehensive Approaches in NASH Therapeutics
- Efficacy and Safety of Aldafermin in Non-Alcoholic Steatohepatitis: A systematic review and meta-analysis of randomized controlled trials
- White Adipose Tissue in Metabolic Associated Fatty Liver Disease
- Probabilistic Scatter Plots for Visualizing Carbohydrate and Lipid Metabolism States in Non-Alcoholic Fatty Liver Disease
- Artificial Intelligence Chatbots in Healthcare: Navigating Accuracy, Privacy, and Global Applicability
- Roflumilast ameliorates GAN diet-induced non-alcoholic fatty liver disease by reducing hepatic steatosis and fibrosis in ob/ob mice
- The Transition in Terminology: From Non-alcoholic Fatty Liver Disease (NAFLD) to Metabolic Dysfunction-associated Fatty Liver Disease (MAFLD) to Metabolic-associated Steatotic Liver Disease (MASLD)
- EASL-EASD-EASO Clinical Practice Guidelines on the management of metabolic dysfunction-associated steatotic liver disease (MASLD)
- Resmetirom, the long-awaited first treatment for metabolic dysfunction-associated steatohepatitis and liver fibrosis?
- Comparative and Predictive Significance of Serum Leptin Levels in Non-alcoholic Fatty Liver Disease
- Recruitment or activation of mast cells in the liver aggravates the accumulation of fibrosis in carbon tetrachloride-induced liver injury
- Response to: The Synergism of Public Health Policies and Social Work May Reduce Mortality from Cancer, Liver Disease and Cardiovascular Disease
- THE GLOBAL EPIDEMIOLOGY OF NON-ALCOHOLIC FATTY LIVER DISEASE AND NON-ALCOHOLIC STEATOHEPATITIS AMONG PATIENTS WITH TYPE 2 DIABETES
- Serum miR‑29 is increased in mice with early liver fibrosis
- Myeloid AMPK signaling restricts fibrosis but is not required for metformin improvements during CDAHFD-induced NASH in mice
- Progress of mesenchymal stem cells (MSCs) & MSC-Exosomes combined with drugs intervention in liver fibrosis
- Chronic unpredictable mild stress increases serum aldosterone without affecting corticosterone levels and induces hepatic steatosis and renal injury in young adult male rats
- Angiocrine signaling in sinusoidal homeostasis and liver diseases
- Coronary artery disease as a risk factor for metabolic dysfunction-associated steatotic liver disease and liver fibrosis
- Inflammation in alcohol-associated hepatitis: pathogenesis and therapeutic targets
- Incretin-based investigational therapies for the treatment of MASLD/MASH
- Increased phosphatidylcholine and its hydroperoxides in serum low-density lipoproteins from patients with non-alcoholic steatohepatitis
- Increased phosphatidylcholine and its hydroperoxides in serum low-density lipoproteins from patients with non-alcoholic steatohepatitis
- Author's reply: The importance of professional training to foster the implementation of Artificial Intelligence in the clinical setting of liver diseases
- Letter to the editor: Relationship between educational attainment and non-alcoholic fatty liver disease: A two-sample Mendelian randomization study
- The role and mechanism of SUMO modification in liver disease
- Multiscale 3D genome organization underlies duck fatty liver with no adipose inflammation or serious injury
- Targeting antioxidant factor Nrf2 by raffinose ameliorates lipid dysmetabolism-induced pyroptosis, inflammation and fibrosis in NAFLD
- Semaglutide alters gut microbiota and improves NAFLD in db/db mice
- A model of alcoholic liver disease based on different hepatotoxics leading to liver cancer
- Coexistence of metabolic-associated fatty liver disease and autoimmune or toxic liver disease
- Vitamin D(3) exacerbates steatosis while calcipotriol inhibits inflammation in non-alcoholic fatty liver disease in Sod1 knockout mice: a comparative study of two forms of vitamin D
- Regulatory pathways and therapeutic potential of PDE4 in liver pathophysiology
- Androsin alleviates non-alcoholic fatty liver disease by activating autophagy and attenuating de novo lipogenesis
- Autoantibodies against acetylcholine receptors are increased in archived serum samples from patients with schizophrenia
- Antipsychotics use in autoimmune encephalitis and multiple sclerosis: Impact on hospitalization duration
- Chronic exposure to ambient air pollution and the risk of non-alcoholic fatty liver disease: A cross-sectional study in Taiwan and Hong Kong
- Dynamics and prognostic value of serum neurofilament light chain in Guillain-Barré syndrome
- Baricitinib treatment in children with COPA syndrome
- The challenge of artificial intelligence in medical writing and editing
- Radiation Therapy for the Management of Renal Medullary Carcinoma: A Multi-Case Study
- Tartaric acid ameliorates experimental non-alcoholic fatty liver disease by activating the AMP-activated protein kinase signaling pathway
- Tartaric acid ameliorates experimental non-alcoholic fatty liver disease by activating the AMP-activated protein kinase signaling pathway
- Author's reply: AI in medicine, bridging the chasm between potential and capability
- Quantitative measurements of M2BPGi depend on liver fibrosis and inflammation
- Quantitative measurements of M2BPGi depend on liver fibrosis and inflammation
- Characterizing cognitive heterogeneity in first-episode psychosis
- Investigating delirium in stroke with an EEG lens: Focal lesions with global impact?
- Lime-Induced Phytophotodermatitis: A Rash That Requires Explicit Questioning
- Artificial intelligence in medicine: Ethical, deontological aspects and the impact on the doctor-patient relationship
- Association of Histopathological and Biochemical Aspects of NAFLD With the Severity of Liver Fibrosis in Individuals With Obesity: Cross-sectional Study
- A PROTEIN COMPLEX OF LIVER ORIGIN ACTIVATES A PRO-INFLAMMATORY PROGRAM THAT DRIVES HEPATIC AND INTESTINAL INJURY IN ALCOHOL-ASSOCIATED LIVER DISEASE
- A PROTEIN COMPLEX OF LIVER ORIGIN ACTIVATES A PRO-INFLAMMATORY PROGRAM THAT DRIVES HEPATIC AND INTESTINAL INJURY IN ALCOHOL-ASSOCIATED LIVER DISEASE
- When Combating Dementia in Patients With Atrial Fibrillation Do Not Forget the Missing Bullet Holes
- When Combating Dementia in Patients With Atrial Fibrillation Do Not Forget the Missing Bullet Holes
- When Combating Dementia in Patients With Atrial Fibrillation Do Not Forget the Missing Bullet Holes
- Letter Re: Hepatocellular and extrahepatic cancers in non-alcoholic fatty liver disease: A systematic review and meta-analysis
- Galectin-3 and Severity of Liver Fibrosis in Metabolic Dysfunction-Associated Fatty Liver Disease
- Patients with Suicidal Ideation for Outpatient Surgery at Freestanding Ambulatory Surgery Centers: How Do We Decide to Proceed or to Postpone?
- ADHD, sleep, chronotype and health in a large cohort of Dutch nurses
- Autism spectrum disorder in children and young people with FND
Evidence Blueprint
Abnormal liver steatosis and fibrosis serum biomarker levels among psychiatric inpatients
☊ AI-Driven Related Evidence Nodes
(recent articles with at least 5 words in title)
More Evidence
Abnormal liver steatosis and fibrosis serum biomarker levels among psychiatric inpatients
🌐 365 Days
AI Virtual Reality Related Evidence Matrix
- Abnormal liver steatosis and fibrosis serum biomarker levels among psychiatric inpatients
- Aspirin for Non Alcoholic Fatty Liver Disease: Promising but Inconclusive - A Letter to the editor
- Metabolism-related signalling pathways involved in the pathogenesis and development of metabolic dysfunction-associated steatotic liver disease
- Use of PNPLA3, TM6SF2, and HSD17B13 for detection of fibrosis in MASLD in the general population
- Factors Associated with Discordance in the Assessment of Fibrosis Stage between Transient Elastography and Liver Biopsy in NAFLD Patients
- The Pan Immune Inflammatory Value in Relation to Non-Alcoholic Fatty Liver Disease and Hepatic Fibrosis
- Resmetirom's Approval: Highlighting the Need for Comprehensive Approaches in NASH Therapeutics
- Efficacy and Safety of Aldafermin in Non-Alcoholic Steatohepatitis: A systematic review and meta-analysis of randomized controlled trials
- White Adipose Tissue in Metabolic Associated Fatty Liver Disease
- Increased Risk of Colorectal Adenomas with Metabolic-Associated Fatty Liver Disease Components
- Effects of Saroglitazar in the Treatment of Non-alcoholic Fatty Liver Disease or Non-alcoholic Steatohepatitis: A Systematic Review and Meta-analysis
- Probabilistic Scatter Plots for Visualizing Carbohydrate and Lipid Metabolism States in Non-Alcoholic Fatty Liver Disease
- Independent and joint association of physical activity and adequate weekday sleep duration with metabolic dysfunction-associated steatotic liver disease
- Satellite liver transplant centres significantly improve transplant assessment outcomes for patients with chronic liver disease but not hepatocellular carcinoma: a retrospective cohort study
- Granulocyte Colony Stimulating Factor in decompensated cirrhosis, acute alcoholic hepatitis, and acute-on-chronic liver failure: a comprehensive meta-analysis of randomized controlled trials
- Artificial Intelligence Chatbots in Healthcare: Navigating Accuracy, Privacy, and Global Applicability
- Roflumilast ameliorates GAN diet-induced non-alcoholic fatty liver disease by reducing hepatic steatosis and fibrosis in ob/ob mice
- Corrigendum to "SIRT5 rs12216101 T>G variant is associated with liver damage and mitochondrial dysfunction in patients with non-alcoholic fatty liver disease" [J Hepatol 80 (2024) 10-19]
- The Transition in Terminology: From Non-alcoholic Fatty Liver Disease (NAFLD) to Metabolic Dysfunction-associated Fatty Liver Disease (MAFLD) to Metabolic-associated Steatotic Liver Disease (MASLD)
- Compromised very-low density lipoprotein induced polyunsaturated triglyceride accumulation in N-nitrosodiethylamine-induced hepatic steatosis
- EASL-EASD-EASO Clinical Practice Guidelines on the management of metabolic dysfunction-associated steatotic liver disease (MASLD)
- Resmetirom, the long-awaited first treatment for metabolic dysfunction-associated steatohepatitis and liver fibrosis?
- Comparative and Predictive Significance of Serum Leptin Levels in Non-alcoholic Fatty Liver Disease
- ALT Poorly Predicts Nonalcoholic Fatty Liver Disease (NAFLD) and Liver Fibrosis as Determined by Vibration-Controlled Transient Elastography in Adult National Health and Nutrition Examination Survey 2017-2018: ALT Poorly Predicts NAFLD and…
- Recruitment or activation of mast cells in the liver aggravates the accumulation of fibrosis in carbon tetrachloride-induced liver injury
- Evaluation of Antisense Oligonucleotides Therapy Targeting Hsd17b13 in a Fibrosis Mice Model
- Response to: The Synergism of Public Health Policies and Social Work May Reduce Mortality from Cancer, Liver Disease and Cardiovascular Disease
- THE GLOBAL EPIDEMIOLOGY OF NON-ALCOHOLIC FATTY LIVER DISEASE AND NON-ALCOHOLIC STEATOHEPATITIS AMONG PATIENTS WITH TYPE 2 DIABETES
- Serum miR‑29 is increased in mice with early liver fibrosis
- Role of Angiotensin II in Non-Alcoholic Steatosis Development
- Performance of FibroScan in grading steatosis and fibrosis in patients with nonalcoholic fatty liver disease: A meta-analysis
- ALCOHOLIC FOAMY DEGENERATION, AN ENTITY RESEMBLING ALCOHOL-ASSOCIATED HEPATITIS: DIAGNOSIS, PROGNOSIS AND MOLECULAR PROFILING
- Myeloid AMPK signaling restricts fibrosis but is not required for metformin improvements during CDAHFD-induced NASH in mice
- Targeted platelet with hydrogen peroxide responsive behavior for non-alcoholic steatohepatitis detection
- Progress of mesenchymal stem cells (MSCs) & MSC-Exosomes combined with drugs intervention in liver fibrosis
- Chronic unpredictable mild stress increases serum aldosterone without affecting corticosterone levels and induces hepatic steatosis and renal injury in young adult male rats
- Various types of fasting diet and possible benefits in nonalcoholic fatty liver: Mechanism of actions and literature update
- The protective effect of Enteromorpha prolifera polysaccharide on alcoholic liver injury in C57BL/6 mice
- Angiocrine signaling in sinusoidal homeostasis and liver diseases
- Coronary artery disease as a risk factor for metabolic dysfunction-associated steatotic liver disease and liver fibrosis
- A Novel cause of Massive Hepatosplenomegaly with Fibrosis in two children: Transient Infantile Hypertriglyceridemia
- Inflammation in alcohol-associated hepatitis: pathogenesis and therapeutic targets
- Incretin-based investigational therapies for the treatment of MASLD/MASH
- Increased phosphatidylcholine and its hydroperoxides in serum low-density lipoproteins from patients with non-alcoholic steatohepatitis
- Increased phosphatidylcholine and its hydroperoxides in serum low-density lipoproteins from patients with non-alcoholic steatohepatitis
- Fibroblast growth factor 19 alters bile acids to induce dysbiosis in mice with alcohol-induced liver disease
- Fibroblast growth factor 19 alters bile acids to induce dysbiosis in mice with alcohol-induced liver disease
- Specific targeting of the NRF2/β-TrCP axis promotes beneficial effects in NASH
- Author's reply: The importance of professional training to foster the implementation of Artificial Intelligence in the clinical setting of liver diseases
- Imbalance of mitochondrial fusion in peripheral blood mononuclear cells is associated with liver fibrosis in patients with metabolic dysfunction-associated steatohepatitis
- Letter to the editor: Relationship between educational attainment and non-alcoholic fatty liver disease: A two-sample Mendelian randomization study
- The role and mechanism of SUMO modification in liver disease
- Increased frequency of hepatic steatosis and fibrosis in patients with gout detected by transient elastography
- Diagnostic Performance of Quantitative Ultrasound Parameters in Non-alcoholic Fatty Liver Disease
- Brain-derived neurotrophic factor levels across psychiatric disorders: A systemic review and network meta-analysis
- Performance of non-invasive tests for liver fibrosis and resolution after bariatric surgery
- Multiscale 3D genome organization underlies duck fatty liver with no adipose inflammation or serious injury
- Targeting antioxidant factor Nrf2 by raffinose ameliorates lipid dysmetabolism-induced pyroptosis, inflammation and fibrosis in NAFLD
- Corrigendum to "Phase 2, placebo-controlled clinical study of oral ganaxolone in PCDH19-clustering epilepsy" [Epilepsy Res. (2023) 191 107112]
- Corrigendum to "Phase 2, placebo-controlled clinical study of oral ganaxolone in PCDH19-clustering epilepsy" [Epilepsy Res. (2023) 191 107112]
- Semaglutide alters gut microbiota and improves NAFLD in db/db mice
- A model of alcoholic liver disease based on different hepatotoxics leading to liver cancer
- Coexistence of metabolic-associated fatty liver disease and autoimmune or toxic liver disease
- Liver fibrosis in pars cohort study: A large-scale study on the prevalence and correlated factors